Novartis Triumphs At EMA With Jetrea, But Merck Has Suspension of Three Merck Products Confirmed
This article was originally published in The Pink Sheet Daily
The EMA has given the nod to Novartis subsidiary Alcon’s vitreomacular traction drug Jetrea and agreed to an indication extension for its Ilaris product to treat gouty arthritis. EMA’s Committee for Medicinal Products for Human Use also confirmed a recommendation to suspend the marketing authorizations of three Merck Sharp & Dohme products used to treat adults with dyslipidemia.
You may also be interested in...
Germany’s IQWiG has backed Novartis’ Jetrea for VMT, albeit with restricted indication, but knocked back Almirall’s Constella, citing study irrelevance.
NICE has rejected Bosulif for leukemia principally on cost grounds, but also due to a lack of comprehensive long-term data, which is also being sought by the EMA.
VentureHealth combines the best in venture and crowdfunding, and has two exits to show for it. Plus Valeant buys Bausch & Lomb, GSK buys Okairos, AZ buys Omthera, while ThromboGenics/Array, Pfizer/UCSF, and Amgen/Astellas do deals.